Protalix BioTherapeutics
PLX
35 hedge funds and large institutions have $56.7M invested in Protalix BioTherapeutics in 2015 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 9 closing their positions.
143% more call options, than puts
Call options by funds: $233K | Put options by funds: $96K
0.03% more ownership
Funds ownership: 3.08% → 3.11% (+0.03%)
3% less capital invested
Capital invested by funds: $58.4M → $56.7M (-$1.72M)
5% less funds holding
Funds holding: 37 → 35 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 2 |
VAM
Visium Asset Management
New York
|
+$5.19M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$442K |
| 4 |
Jane Street
New York
|
+$222K |
| 5 |
VanEck Associates
New York
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.3M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.93M |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
-$917K |
| 5 |
BlackRock
New York
|
-$604K |
PLX Hedge Fund Activity: Q2 2015 in Review
35 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2015, worth a combined $56.7M — down 2.9% from $58.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLX and 7 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $15.1M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10M sold.
- 35 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2015, down from 37 in Q1 2015.
- Funds reported $56.7M of Protalix BioTherapeutics stock for Q2 2015, down 2.9% quarter-over-quarter.
- 7 funds opened new Protalix BioTherapeutics positions in Q2 2015 and 9 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2015 was Camber Capital Management, an estimated $15.1M added.
- The largest Protalix BioTherapeutics seller in Q2 2015 was Consonance Capital Management, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2015.